title: [The effect of antibiotic therapy on the immune status of patients with nonspecific lung diseases complicated by pleural empyema].
abstract: The immunity status was studied in patients with acute pyo-destructive lung diseases complicated by purulent pleurisy (relative counts of T- and B-lymphocytes, subpopulation composition of T-cells, numbers of lymphocytes-killers, and functional state of neutrophils of the peripheral blood). These patients revealed significant cellular immunodeficiency, rise in B-lymphocytes, and apparent changes in the activity of the peripheral blood phagocytes. The endolymphatic drug route was found out to be superior to conventional ones in that it had more expressed normalizing action on the quantitative and functional state of T-lymphocytes, their subpopulation composition (manifested by augmentation of T-cells-helpers), as well as on the level of B-lymphocytes, lymphocytes-killers, and metabolic activity of neutrophils of the peripheral blood.
authors.forename: N S
authors.initials: NS
authors.lastname: Opanasenko
authors.forename: Ia I
authors.initials: IaI
authors.lastname: Pristaĭko
authors.forename: R I
authors.initials: RI
authors.lastname: Karnakh
authors.forename: Ia M
authors.initials: IaM
authors.lastname: Voloshin
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016724:Empyema, Pleural / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007272:Injections, Intralymphatic; D008173:Lung Diseases, Obstructive / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D018655:Lymphocyte Count / Q000187:drug effects; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents
vernacular_title: Vliianie antibiotikoterapii na immunnyĭ status bol'nykh s nespetsificheskimi zabolevaniiami legkikh, oslozhnennykh émpiemoĭ plevry.